Category - News

Executive Moves

Jerry Isaacson joins Roth as managing director and senior research analyst

Jerry Isaacson has joined Roth Capital Partners as a managing director and senior research analyst covering biotechnology and emerging therapeutics.

November 5, 2018

Markets

Roth ups Syros Pharma to buy; maintains $12 PT

Roth Capital Partners upgraded Syros Pharmaceuticals (NASDAQ:SYRS) to “buy” but maintained its $12 price target, citing recent erosion of the company’s market value. The stock closed at $7.76 on Nov. 2 after trading...

November 5, 2018

Markets

Ladenburg starts Aptevo Therapeutics at buy; PT $14

Ladenburg Thalmann initiated coverage of Aptevo Therapeutics (NASDAQ:APVO) with a “buy” rating and $14 price target. The stock closed at $3.63 on Nov. 2. Aptevo is developing biotherapeutics for oncology and autoimmune...

November 5, 2018

Markets

HCW cuts Trevena to neutral and PT to 75 cents from $3

H.C. Wainwright downgraded Trevena (NASDAQ:TRVN) to “neutral” from “buy” and slashed its price target to 75 cents from $3 after the company received a complete response letter (CRL) on Nov. 2 from the FDA for...

November 5, 2018

Developments

Constellation Brands closes $5-billion investment in Canopy Growth

Constellation Brands (NYSE:STZ) closed its $5-billion (Canadian) investment in Canopy Growth (TSX:WEED; NYSE:CGC) following approval by Canopy shareholders and all regulatory agencies, including the Canadian government...

November 1, 2018

Developments

elminda, Villages Health joint study receives Erickson Foundation aging award

A joint research project between closely-held elminda of Israel and The Villages Health of Florida will receive the prestigious Erickson Foundation Award for Excellence in Aging Research at the upcoming 2018 American...

November 1, 2018

Developments

Scientus Pharma updates buccal cannabis spray development collaboration with Generex

Closely-held Scientus Pharma updated its collaboration with Generex Biotechnology (OTCQB:GNBT) to co-develop products for the delivery of cannabinoids via the buccal mucosa, or inner lining of the mouth. Having recently...

October 31, 2018

Markets

Leerink cuts Clovis Oncology PT to $22 from $30

Leerink lowered its price target for Clovis Oncology (NASDAQ:CLVS) to $22 from $30 but maintained its “market perform” rating after the company reported third quarter results. The stock closed at $16.61 on Oct. 30...

October 31, 2018

Developments

IntelGenx partner receives marketing clearance for RIZAPORT in Spain

IntelGenx’s (TSXV:IGX; OTCQX:IGXT) commercialization partner, Groupo Juste, which is now part of Exceltis Healthcare, has received national marketing authorization for RIZAPORT 10 mg from the Spanish Agency of Medicines...

October 31, 2018

Markets

Maxim starts Adial Pharma at buy; PT $5

Maxim Group initiated coverage of Adial Pharmaceuticals (NASDAQ:ADIL) with a “buy” rating and $5 price target. The stock closed at $1.88 on Oct. 29. Adial is developing AD04, an ultra-low-dose ondansetron therapy for...

October 30, 2018

Category - News

Subscribe